Current Edition

Assessing Cardiac Safety in Oncological Drug Development

Advances in the development of anticancer drugs have decreased mortality rates for many cancers and increased patient survival. However, concerns have been raised about possible long-term effects of these new anticancer agents, such as cardiovascular toxicity. Alexandre Durand-Salmon and Joe-Elie Salem at Banook Group show why assessing cardiac safety is imperative in drug development.